CytoSorbents announced that CytoSorb was granted an expanded medical device registration by the Brazilian Health Regulatory Agency, ANVISA, to treat shock. After receiving its first ANVISA registration in September 2020 to treat cytokine storm in cardiac surgery and critical illnesses such as COVID-19 in the midst of the COVID pandemic, CytoSorb has now received an expanded ANVISA registration to also include the treatment of shock – a common and frequently fatal complication of critical illness and cardiac surgery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTSO:
- CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
- CytoSorbents reports Q2 EPS (14c), consensus (11c)
- CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
- Cytosorbents Corp (CTSO) Q2 Earnings Cheat Sheet
- CytoSorbents to Report Second Quarter 2023 Operating and Financial Results